Literature DB >> 21056576

Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting.

Birgit Dreier1, Galina Mikheeva, Natalya Belousova, Petra Parizek, Edgar Boczek, Ilian Jelesarov, Patrik Forrer, Andreas Plückthun, Victor Krasnykh.   

Abstract

Adenoviruses (Ads) hold great promise as gene vectors for diagnostic or therapeutic applications. The native tropism of Ads must be modified to achieve disease site-specific gene delivery by Ad vectors and this should be done in a programmable way and with technology that can realistically be scaled up. To this end, we applied the technologies of designed ankyrin repeat proteins (DARPins) and ribosome display to develop a DARPin that binds the knob domain of the Ad fiber protein with low nanomolar affinity (K(D) 1.35 nM) and fused this protein with a DARPin specific for Her2, an established cell-surface biomarker of human cancers. The stability of the complex formed by this bispecific targeting adapter and the Ad virion resulted in insufficient gene transfer and was subsequently improved by increasing the valency of adapter-virus binding. In particular, we designed adapters that chelated the knob in a bivalent or trivalent fashion and showed that the efficacy of gene transfer by the adapter-Ad complex increased with the functional affinity of these molecules. This enabled efficient transduction at low stoichiometric adapter-to-fiber ratios. We confirmed the Her2 specificity of this transduction and its dependence on the Her2-binding DARPin component of the adapters. Even the adapter molecules with four fused DARPins could be produced and purified from Escherichia coli at very high levels. In principle, DARPins can be generated against any target and this adapter approach provides a versatile strategy for developing a broad range of disease-specific gene vectors. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21056576      PMCID: PMC3149894          DOI: 10.1016/j.jmb.2010.10.040

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  76 in total

Review 1.  Genetic targeting of adenoviral vectors.

Authors:  V N Krasnykh; J T Douglas; V W van Beusechem
Journal:  Mol Ther       Date:  2000-05       Impact factor: 11.454

2.  Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge.

Authors:  Nikolay Korokhov; Galina Mikheeva; Alexander Krendelshchikov; Natalya Belousova; Vera Simonenko; Valentina Krendelshchikova; Alexander Pereboev; Alexander Kotov; Olga Kotova; Pierre L Triozzi; Wayne A Aldrich; Joanne T Douglas; Kin-Ming Lo; Papia T Banerjee; Stephen D Gillies; David T Curiel; Victor Krasnykh
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 3.  How does your virus grow? Understanding and interfering with virus assembly.

Authors:  Adam Zlotnick; Stephen J Stray
Journal:  Trends Biotechnol       Date:  2003-12       Impact factor: 19.536

4.  Designed ankyrin repeat proteins: a novel tool for testing epidermal growth factor receptor 2 expression in breast cancer.

Authors:  Jean-Philippe Theurillat; Birgit Dreier; Gabriela Nagy-Davidescu; Burkhardt Seifert; Silvia Behnke; Ursina Zürrer-Härdi; Fabienne Ingold; Andreas Plückthun; Holger Moch
Journal:  Mod Pathol       Date:  2010-05-21       Impact factor: 7.842

5.  Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors.

Authors:  Raul Alba; Angela C Bradshaw; Lynda Coughlan; Laura Denby; Robert A McDonald; Simon N Waddington; Suzanne M K Buckley; Jenny A Greig; Alan L Parker; Ashley M Miller; Hongjie Wang; Andre Lieber; Nico van Rooijen; John H McVey; Stuart A Nicklin; Andrew H Baker
Journal:  Blood       Date:  2010-07-07       Impact factor: 22.113

6.  Targeting adenoviruses with factor x-single-chain antibody fusion proteins.

Authors:  Christopher Y Chen; Shannon M May; Michael A Barry
Journal:  Hum Gene Ther       Date:  2010-06       Impact factor: 5.695

7.  Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target.

Authors:  Christian Zahnd; Patrick Amstutz; Andreas Plückthun
Journal:  Nat Methods       Date:  2007-03       Impact factor: 28.547

8.  Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries.

Authors:  Patrick Amstutz; Holger Koch; H Kaspar Binz; Stefan A Deuber; Andreas Plückthun
Journal:  Protein Eng Des Sel       Date:  2006-03-21       Impact factor: 1.650

Review 9.  New protein engineering approaches to multivalent and bispecific antibody fragments.

Authors:  A Plückthun; P Pack
Journal:  Immunotechnology       Date:  1997-06

10.  High-affinity binders selected from designed ankyrin repeat protein libraries.

Authors:  H Kaspar Binz; Patrick Amstutz; Andreas Kohl; Michael T Stumpp; Christophe Briand; Patrik Forrer; Markus G Grütter; Andreas Plückthun
Journal:  Nat Biotechnol       Date:  2004-04-18       Impact factor: 54.908

View more
  21 in total

1.  A designed ankyrin repeat protein selected to bind to tubulin caps the microtubule plus end.

Authors:  Ludovic Pecqueur; Christian Duellberg; Birgit Dreier; Qiyang Jiang; Chunguang Wang; Andreas Plückthun; Thomas Surrey; Benoît Gigant; Marcel Knossow
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

2.  DARPins: an efficient targeting domain for lentiviral vectors.

Authors:  Robert C Münch; Michael D Mühlebach; Thomas Schaser; Sabrina Kneissl; Christian Jost; Andreas Plückthun; Klaus Cichutek; Christian J Buchholz
Journal:  Mol Ther       Date:  2011-01-11       Impact factor: 11.454

3.  Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters.

Authors:  Birgit Dreier; Annemarie Honegger; Christian Hess; Gabriela Nagy-Davidescu; Peer R E Mittl; Markus G Grütter; Natalya Belousova; Galina Mikheeva; Victor Krasnykh; Andreas Plückthun
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

4.  Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T Cells.

Authors:  Elizabeth Siegler; Si Li; Yu Jeong Kim; Pin Wang
Journal:  Hum Gene Ther       Date:  2017-06-22       Impact factor: 5.695

5.  DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety.

Authors:  Katrin Friedrich; Jan Rh Hanauer; Steffen Prüfer; Robert C Münch; Iris Völker; Christodoulos Filippis; Christian Jost; Kay-Martin Hanschmann; Roberto Cattaneo; Kah-Whye Peng; Andreas Plückthun; Christian J Buchholz; Klaus Cichutek; Michael D Mühlebach
Journal:  Mol Ther       Date:  2013-02-05       Impact factor: 11.454

6.  Frontiers in Suicide Gene Therapy of Cancer.

Authors:  Marek Malecki
Journal:  J Genet Syndr Gene Ther       Date:  2012-10-22

7.  Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer.

Authors:  Robert C Münch; Hanna Janicki; Iris Völker; Anke Rasbach; Michael Hallek; Hildegard Büning; Christian J Buchholz
Journal:  Mol Ther       Date:  2012-09-11       Impact factor: 11.454

Review 8.  Retargeting adenoviruses for therapeutic applications and vaccines.

Authors:  Michael A Barry; Jeffrey D Rubin; Shao-Chia Lu
Journal:  FEBS Lett       Date:  2020-02-03       Impact factor: 4.124

9.  The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody.

Authors:  Sheena N Smith; Rajib Schubert; Branko Simic; Dominik Brücher; Markus Schmid; Niels Kirk; Patrick C Freitag; Viviana Gradinaru; Andreas Plückthun
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-25       Impact factor: 11.205

10.  Spatiotemporally confined red light-controlled gene delivery at single-cell resolution using adeno-associated viral vectors.

Authors:  Maximilian Hörner; Carolina Jerez-Longres; Anna Hudek; Sebastian Hook; O Sascha Yousefi; Wolfgang W A Schamel; Cindy Hörner; Matias D Zurbriggen; Haifeng Ye; Hanna J Wagner; Wilfried Weber
Journal:  Sci Adv       Date:  2021-06-16       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.